Table 3.
Changes in levels and trends of, and absolute and relative changes in individual price-negotiated medication cost per DDD, procurement volume and spending
| Price-negotiated medications | Baseline | Change after intervention | Change 6 months after intervention | Change at the end of observation | ||||
| Level | Trend | Level | Trend | Absolute | Relative (%) | Absolute | Relative (%) | |
| Cost per DDD (US$/DDD) | ||||||||
| Trastuzumab | 155.57*** | −1.65*** | −55.75*** | −0.26*** | −57.29*** | −50.83 | −59.08*** | −58.40 |
| Bortezomib | 460.65*** | −5.55*** | −108.07*** | −0.23*** | −109.47*** | −34.59 | −111.11*** | −40.02 |
| Recombinant human endostatin | 228.69*** | −2.02*** | −35.62*** | 0.58*** | −32.12*** | −18.24 | −28.04*** | −17.31 |
| Erlotinib | 94.15*** | −1.87*** | −22.69*** | 1.02*** | −16.58*** | −36.48 | −9.46 | −29.25 |
| Sorafenib | 246.21*** | −1.23* | −111.12*** | −2.51*** | −126.16*** | −58.87 | −143.7*** | −69.85 |
| Nimotuzumab | 146.75*** | −1.98*** | −26.46*** | 0.57*** | −23.02*** | −24.20 | −19.01 | −23.40 |
| Rituximab | 951.44*** | −7.49*** | −215.69*** | 3.79*** | −192.94*** | −25.50 | −166.4*** | −23.62 |
| Bevacizumab | 198.88*** | −1.94*** | −64.31*** | −0.58*** | −67.80*** | −45.68 | −71.88*** | −53.30 |
| Fulvestrant | 26.83*** | −0.08*** | −13.30*** | −0.05*** | −13.63*** | −55.05 | −14.01*** | −57.89 |
| Lapatinib | 86.40*** | −0.10 | −24.98*** | −3.09*** | −43.52*** | −52.00 | −65.15*** | −78.52 |
| Everolimus | 75.30*** | −0.33*** | −27.16*** | 0.12*** | −26.46*** | −39.63 | −25.63*** | −39.76 |
| Lenalidomide | 185.76*** | −0.02 | −114.32*** | −0.69*** | −118.43*** | −63.94 | −123.23*** | −66.59 |
| Apatinib | 105.38*** | −0.24** | −35.50*** | −0.15*** | −36.43*** | −36.74 | −37.52*** | −38.49 |
| Chidamide | 144.03*** | −0.64*** | −38.90*** | −0.14*** | −39.74*** | −31.19 | −40.73*** | −33.13 |
| Abiraterone | 187.17*** | −0.79*** | −93.69*** | 0.72*** | −89.38*** | −53.67 | −84.35*** | −52.39 |
| Volume (no of DDDs) | ||||||||
| Trastuzumab | 93.35*** | 3.75 | −23.27 | 33.63*** | 178.52*** | 93.59 | 413.94*** | 190.79 |
| Bortezomib | 7.89*** | 0.51*** | 17.98*** | −1.34*** | 9.96*** | 47.00 | 0.60 | 2.41 |
| Recombinant human endostatin | 21.89*** | 0.31** | 6.76** | 0.4*** | 9.17*** | 30.70 | 11.99*** | 37.44 |
| Erlotinib | 30.23*** | 0.53*** | 2.35 | 1.37*** | 10.57*** | 24.09 | 20.17*** | 42.39 |
| Sorafenib | 21.67*** | 0.29 | 12.96 | 5.78*** | 47.64*** | 163.19 | 88.10*** | 282.22 |
| Nimotuzumab | 26.14*** | 0.34 | 17.74*** | 2.34*** | 31.77*** | 90.68 | 48.13*** | 128.60 |
| Rituximab | 8.41*** | 0.29*** | 2.34 | 1.53*** | 11.53*** | 72.11 | 22.26*** | 123.44 |
| Bevacizumab | 32.77*** | 1.97*** | 19.62*** | 15.05*** | 109.93*** | 130.83 | 215.3*** | 220.08 |
| Fulvestrant | 41.79*** | 0.38 | 34.09*** | 16.7*** | 134.26*** | 260.44 | 251.14*** | 463.54 |
| Lapatinib | 10.25* | 0.75 | −7.02 | 4.46*** | 19.77** | 66.53 | 51.02*** | 145.97 |
| Everolimus | 13.27*** | −0.10 | −0.01 | 0.41*** | 2.44 | 22.74 | 5.30** | 52.70 |
| Lenalidomide | 5.84*** | 0.21 | −5.54* | 2.3*** | 8.29*** | 72.69 | 24.42*** | 189.26 |
| Apatinib | 5.34*** | 1.47*** | 0.48 | 1.37*** | 8.69*** | 19.96 | 18.27*** | 33.94 |
| Chidamide | −0.30 | 0.17** | 4.29*** | 0.63*** | 8.07*** | 198.04 | 12.49*** | 237.57 |
| Abiraterone | 3.92* | 0.19 | 8.79** | 6.56*** | 48.17*** | 549.62 | 94.12*** | 934.69 |
| Spending (US$) | ||||||||
| Trastuzumab | 15377.32*** | 310.38** | −12360.62*** | 1108.81*** | −5707.79** | −24.34 | 2053.84 | 8.02 |
| Bortezomib | 3911.54*** | 128.15*** | 1507.93*** | −423.41*** | −1032.53** | −14.25 | −3996.39*** | −49.09 |
| Recombinant human endostatin | 4983.48*** | 21.99 | −276.99 | 37.53*** | −51.83 | −0.93 | 210.86 | 3.69 |
| Erlotinib | 2970.76*** | −32.48*** | −833.64*** | 40.52*** | −590.52** | −27.77 | −306.87 | −16.16 |
| Sorafenib | 5306.88*** | 37.32* | −1882.34*** | 281.62*** | −192.60 | −3.07 | 1778.75*** | 27.20 |
| Nimotuzumab | 3974.38*** | −16.77 | −0.72 | 157.25*** | 942.80 | 26.65 | 2043.57** | 59.74 |
| Rituximab | 8350.76*** | 171.62*** | −2785.27*** | 804.79*** | 2043.47*** | 15.95 | 7676.99*** | 54.78 |
| Bevacizumab | 6962.73*** | 258.54*** | −4440.06*** | 719.03*** | −125.89 | −0.92 | 4907.31*** | 31.67 |
| Fulvestrant | 1126.59*** | 5.97 | −247.60 | 164.26*** | 737.93*** | 57.57 | 1887.71*** | 142.63 |
| Lapatinib | 877.3*** | 64.37** | −682.04 | −31.6*** | −871.64*** | −34.17 | −1092.84 | −36.41 |
| Everolimus | 997.63*** | −11.09* | −296.67** | 20.01*** | −176.58 | −24.89 | −36.48 | −5.77 |
| Lenalidomide | 1201.93*** | 29.48 | −1353.46*** | 114.9*** | −664.09 | −33.74 | 140.19 | 6.45 |
| Apatinib | 596.74*** | 145.21*** | −1171.08*** | 9.64*** | −1113.27*** | −25.46 | −1045.82*** | −19.41 |
| Chidamide | −44.18 | 15.7** | 443.86*** | 42.48*** | 698.76*** | 192.00 | 996.14*** | 210.24 |
| Abiraterone | 735.93*** | 30.16* | −54.39 | 483.01*** | 2843.68*** | 187.08 | 6224.77*** | 359.58 |
US$ in 2016.
*P<0.05, **p<0.01, ***p<0.001.
CI, confidence interval; DDD, defined daily doses.